Initial phase of human trial for nociceptin receptor agonist enrolls first participants

Grünenthal Announces Enrollment of First Participants in Phase I Clinical Trial for NOP Receptor Agonist Aachen, Germany, 22 October 2024 – Grünenthal, a global leader in pain management and related diseases, has announced the enrollment of the first participants in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial, which aims to demonstrate a favorable…

Source